Innate Pharma (IPHA) Operating Income (2020 - 2025)
Innate Pharma's (IPHA) quarterly Operating Income came in at -$28.8 million in Q2 2025, down 1.57% YoY from -$29.2 million in Q2 2024, and down 1.57% on a QoQ basis from -$28.3 million in Q2 2024.
Innate Pharma (IPHA) Operating Income (2020 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 5 years of Operating Income data on file, last reported at -$28.8 million in Q2 2025.
- Quarterly Operating Income fell 1.57% year-over-year to -$28.8 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$112.3 million (up 1.61% YoY) and the FY2025 annual result came in at -$62.9 million, down 14.07% from the prior year.
- Operating Income eased to -$28.8 million in Q2 2025, from -$28.3 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$433391.9 in Q2 2023 to a low of -$54.7 million in Q4 2021.
- A 4-year average of -$28.6 million and a median of -$28.8 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2024 — Operating Income tumbled 6438.23% — and 2025, when it retreated 1.57%.
- Tracing IPHA's Operating Income over 4 years: stood at -$54.7 million in 2021, then soared by 99.21% to -$433391.9 in 2023, then plunged by 6438.23% to -$28.3 million in 2024, then retreated by 1.57% to -$28.8 million in 2025.
- The last three Operating Income figures came in at -$28.8 million (Q2 2025), -$28.3 million (Q2 2024), and -$433391.9 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Innate Pharma | 187.25 Mn | 187.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -28.78 Mn |
| Jun 30, 2024 | -28.34 Mn |
| Jun 30, 2023 | -433,391.91 |
| Dec 31, 2021 | -54.71 Mn |
| Jun 30, 2021 | -30.62 Mn |
| Jun 30, 2020 | -9.19 Mn |